墨西哥非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学及遗传学方面
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico.
作者信息
Vidal-Cevallos Paulina, Torre Aldo, Mendez-Sanchez Nahum, Uribe Misael, Chavez-Tapia Norberto C
机构信息
Gastroenterology and Obesity Clinic Medica Sur Clinic and Foundation Mexico City Mexico.
Metabolic Unit Department of Gastroenterology Insituto Nacional de Ciencias Médicas y Nutrición "Slavador Zubirán" Tlalpan, Ciudad de México Mexico.
出版信息
Clin Liver Dis (Hoboken). 2022 Mar 10;19(2):68-72. doi: 10.1002/cld.1167. eCollection 2022 Feb.
Abstract
Content available: Author Interview and Audio Recording.
摘要
可获取的内容
作者访谈及音频记录。
相似文献
1
Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico.墨西哥非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学及遗传学方面
Clin Liver Dis (Hoboken). 2022 Mar 10;19(2):68-72. doi: 10.1002/cld.1167. eCollection 2022 Feb.
2
Epidemiological aspects of obesity and NASH/NAFLD in Japan.日本肥胖和 NASH/NAFLD 的流行病学方面。
Hepatol Res. 2005 Oct;33(2):77-82. doi: 10.1016/j.hepres.2005.09.008. Epub 2005 Oct 13.
3
CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.超声造影和瞬时弹性成像技术在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的应用
World J Hepatol. 2014 Jul 27;6(7):496-503. doi: 10.4254/wjh.v6.i7.496.
4
Hepatocellular Carcinoma in Mexico.墨西哥的肝细胞癌
Clin Liver Dis (Hoboken). 2022 Mar 10;19(2):73-77. doi: 10.1002/cld.1196. eCollection 2022 Feb.
5
The Liver and COVID-19 in Mexico.墨西哥的肝脏与新冠肺炎
Clin Liver Dis (Hoboken). 2021 Aug 27;19(2):49-52. doi: 10.1002/cld.1153. eCollection 2022 Feb.
6
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].[非酒精性脂肪性肝病/非酒精性脂肪性肝炎管理概述]
Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.
7
Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.使用多个基因标记的日本非酒精性脂肪性肝病风险评估模型。
PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.
8
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.肌肉脂肪含量与 NASH 密切相关：一项对病态肥胖患者的纵向研究。
J Hepatol. 2021 Aug;75(2):292-301. doi: 10.1016/j.jhep.2021.02.037. Epub 2021 Apr 15.
9
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.胆汁酸谱、组织病理学指标和非酒精性脂肪性肝病进展的遗传变异。
Metabolism. 2021 Mar;116:154457. doi: 10.1016/j.metabol.2020.154457. Epub 2020 Dec 1.
10
and polymorphisms in Brazilian patients with nonalcoholic fatty liver disease.以及巴西非酒精性脂肪性肝病患者的基因多态性。
World J Hepatol. 2020 Oct 27;12(10):792-806. doi: 10.4254/wjh.v12.i10.792.
引用本文的文献
1
Predictive Models for Non-Alcoholic Fatty Liver Disease Diagnosis in Mexican Patients with Gallstone Disease: Sex-Specific Insights.墨西哥胆结石病患者非酒精性脂肪性肝病诊断的预测模型：性别特异性见解
Diagnostics (Basel). 2024 Jul 11;14(14):1487. doi: 10.3390/diagnostics14141487.
2
Personalized Risk Assessment of Hepatic Fibrosis after Cholecystectomy in Metabolic-Associated Steatotic Liver Disease: A Machine Learning Approach.代谢相关脂肪性肝病患者胆囊切除术后肝纤维化的个性化风险评估：一种机器学习方法
J Clin Med. 2023 Oct 12;12(20):6489. doi: 10.3390/jcm12206489.
本文引用的文献
1
Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies.墨西哥的肥胖问题：快速的流行病学转变与食品行业对健康政策的干预。
Lancet Diabetes Endocrinol. 2020 Sep;8(9):746-747. doi: 10.1016/S2213-8587(20)30269-2. Epub 2020 Aug 18.
2
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.全球非肥胖或消瘦非酒精性脂肪性肝病的患病率、发病率和结局：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12.
3
The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider.非酒精性脂肪性肝病患者的诊断及初始诊疗方法：基层医疗服务提供者的作用
Gastroenterol Hepatol Bed Bench. 2019 Fall;12(4):267-277.
4
Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care.非酒精性脂肪性肝病患者在初级保健和医院护理中的检测、诊断和随访建议。
Med Clin (Barc). 2019 Aug 16;153(4):169-177. doi: 10.1016/j.medcli.2019.01.030. Epub 2019 Jun 6.
5
The Mexican consensus on nonalcoholic fatty liver disease.墨西哥非酒精性脂肪性肝病共识
Rev Gastroenterol Mex (Engl Ed). 2019 Jan-Mar;84(1):69-99. doi: 10.1016/j.rgmx.2018.11.007. Epub 2019 Jan 31.
6
High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population.在年轻肥胖的墨西哥人群中，非酒精性脂肪性肝炎和异常肝硬度的流行率很高。
PLoS One. 2019 Jan 4;14(1):e0208926. doi: 10.1371/journal.pone.0208926. eCollection 2019.
7
Prevalence of Metabolic Syndrome in Mexico: A Systematic Review and Meta-Analysis.墨西哥代谢综合征的患病率：一项系统评价与荟萃分析。
Metab Syndr Relat Disord. 2018 Oct;16(8):395-405. doi: 10.1089/met.2017.0157. Epub 2018 Jul 31.
8
Mechanisms of NAFLD development and therapeutic strategies.非酒精性脂肪性肝病发病机制及治疗策略。
Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.
9
A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America.在拉丁美洲的一项多中心队列研究中，肝移植治疗肝细胞癌的病因学情况正在发生变化。
Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):443-452. doi: 10.1016/j.clinre.2018.03.014.
10
Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.酒精性和非酒精性脂肪性肝炎均与心血管风险和肝纤维化相关。
Alcohol. 2018 Jun;69:63-67. doi: 10.1016/j.alcohol.2017.11.004. Epub 2017 Nov 15.
Zotero 插件